A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks’ observational data

• Published in: BMC infectious diseases Vol. 17; no. 1; pp. 658 - 7
• Main Authors: Capetti, Amedeo F., Cossu, Maria Vittoria, Orofino, Giancarlo, Sterrantino, Gaetana, Cenderello, Giovanni, De Socio, Giuseppe V., Cattelan, Anna Maria, Soria, Alessandro, Rusconi, Stefano, Riccardi, Niccolò, Baldin, Gian Maria, Niero, Fosca P., Barbarini, Giorgio, Rizzardini, Giuliano
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 30.09.2017; BioMed Central; BMC
• Subjects: Anti-HIV Agents - therapeutic use; Antiretroviral agents; Antiretroviral drugs; Antiviral drugs; Cancer; Cholesterol; Clinical medicine; Complications; Creatinine; Darunavir; Darunavir - therapeutic use; Dolutegravir; Dosage and administration; Drug abuse; Drug interaction; Drug interactions; Drug resistance; Drug Resistance, Viral; Drug Therapy, Combination; Drugs; Dual; Enzymes; Female; Health aspects; Heterocyclic Compounds, 3-Ring - therapeutic use; High density lipoprotein; HIV; HIV Infections - drug therapy; HIV Infections - virology; HIV-1 - drug effects; HIV-1 - genetics; Human immunodeficiency virus; Humans; Kidney diseases; Liver; Long term health care; Lost to Follow-Up; Low density lipoprotein; Male; Middle Aged; Normality; Plasma; Replication; Ribonucleic acid; Ritonavir; Ritonavir - therapeutic use; RNA; Safety; Salvage; Simplification; Statistical analysis; Substance abuse treatment; Switch; Switching; Therapy; Toxicity; Treatment Outcome; Triglycerides; Viral Load; Viremia; Salvage; Simplification; Darunavir; Switch; Ritonavir; Dual; Dolutegravir

Dolutegravir (DTG) plus darunavir/ritonavir (DRV/r) is a simple combination of drugs that has the best genetic barrier to HIV-1 resistance and may be fit for salvage therapy. All HIV-1-infected subjects treated with DTG plus DRV/r between March 2014 and September 2015 in eight Italian centres were i...